Search results
Showing 1756 to 1770 of 7706 results
Awaiting development [GID-TA10438] Expected publication date: TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]
Suggested remit: To appraise the clinical and cost effectiveness of emicizumab within its marketing authorisation for preventing bleeding episodes in people wit...
In development [GID-QS10113] Expected publication date: TBC
Awaiting development [GID-TA10439] Expected publication date: TBC
Awaiting development [GID-TA10721] Expected publication date: TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention
In development [GID-IP1238] Expected publication date: TBC
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Suggested remit: To appraise the clinical and cost effectiveness of treprostinil sodium within its marketing authorisation for treating chronic thromboembolic p...
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative
Evidence-based recommendations on PeritX for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites.
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers
MRI fusion biopsy systems for diagnosing prostate cancer (DG53)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer
Evidence-based recommendations on transperineal biopsy for diagnosing prostate cancer
Awaiting development [GID-TA10519] Expected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Awaiting development [GID-TA10909] Expected publication date: TBC
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Suggested remit - To appraise the clinical and cost effectiveness of fingolimod within its marketing authorisation for treating relapsing multiple sclerosis in ...